
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing clonazepam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Clonazepam is a Schedule IV controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing clonazepam are listed in tablet form. No finished clonazepam product of any kind is listed in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Clonazepam is a Schedule IV benzodiazepine that compounding pharmacies prepare by prescription as oral suspensions, orally dissolving or topical oral preparations and other non-tablet forms.
Clonazepam is a long-acting benzodiazepine. It enhances the activity of GABA, the brain's main inhibitory neurotransmitter, which reduces abnormal electrical activity and dampens panic. Manufactured clonazepam tablets (Klonopin and generics) are FDA-approved for seizure disorders, including Lennox-Gastaut syndrome, akinetic and myoclonic seizures and absence seizures not controlled by succinimides, and for panic disorder with or without agoraphobia. A prescriber might order compounded clonazepam when a patient needs a strength or liquid that is not manufactured, a dye-free or sugar-free vehicle for a child or tube-fed patient, or a topical oral preparation meant to be held in the mouth. Compounded preparations are not FDA-approved and require a prescription. Clonazepam is a Schedule IV controlled substance under federal law.
Clonazepam carries an FDA boxed warning with three parts. First, taking a benzodiazepine with an opioid can cause profound sedation, slowed breathing, coma and death. Second, abuse, misuse and addiction can occur and can lead to overdose or death, especially with alcohol or other drugs. Third, continued use causes physical dependence, and stopping suddenly or cutting the dose quickly can trigger life-threatening withdrawal, so never stop without a gradual taper set by your prescriber. Like other antiepileptic drugs it can increase suicidal thoughts or behavior; call your prescriber right away for new depression, agitation, aggression or thoughts of self-harm. It causes drowsiness, dizziness, unsteadiness and memory problems, so avoid driving until you know how it affects you, and avoid alcohol and grapefruit. Do not use it if you are allergic to benzodiazepines, have significant liver disease or acute narrow-angle glaucoma; use caution with COPD, sleep apnea or porphyria. Phenytoin, carbamazepine, lamotrigine and phenobarbital lower its levels, and antifungals such as fluconazole raise them. Late-pregnancy use can cause sedation and withdrawal in the newborn; the label reports sedation, poor feeding and poor weight gain in breastfed infants, and LactMed rates it possible with caution and advises watching the baby's drowsiness, weight and milestones. For side effects, talk to your prescriber or pharmacist.
Clonazepam potentiates GABA-A mediated inhibition. Oral absorption is rapid and nearly complete with about 90% absolute bioavailability, peak plasma concentration at 1 to 4 hours, about 85% protein binding, extensive metabolism by reduction of the 7-nitro group with CYP3A involvement, under 2% excreted unchanged, and a typical elimination half-life of 30 to 40 hours. CYP3A inducers (phenytoin, carbamazepine, lamotrigine, phenobarbital) reduce levels by roughly 38%; sertraline, fluoxetine and felbamate do not meaningfully alter its kinetics. Labeled indications: Klonopin (clonazepam tablets) alone or adjunctively for Lennox-Gastaut syndrome, akinetic and myoclonic seizures, and absence seizures refractory to succinimides; and panic disorder with or without agoraphobia, with long-term use periodically reassessed. Prescribers have ordered compounded topical oral clonazepam for burning mouth syndrome (Zur, 2012; Storari et al., 2021), and LactMed cites an expert consensus accepting low-dose clonazepam for refractory restless legs syndrome in lactation; these are off-label. Dosing is per prescriber. Monitor seizure control (worsening of mixed seizure disorders is possible), suicidality, sedation, respiratory status, phenytoin levels when combined, and signs of benzodiazepine use disorder. Clonazepam is DEA Schedule IV. Electronic prescribing of controlled substances is voluntary under federal DEA rules; CMS applies a prescriber-level 70 percent threshold for Medicare Part D controlled substance prescriptions; and a number of states mandate EPCS for some or all controlled substances, with state rules controlling where stricter.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve